Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Clin Cancer Res. 2011 Jun 28;17(15):4975–4986. doi: 10.1158/1078-0432.CCR-10-3328

Figure 1. IL-7 prevents tumor-induced T-cell CD27/28 loss and telomere shortening induced by both hematopoietic and solid tumors in vitro.

Figure 1

Purified T cells were incubatd with various tumor cell lines (Tu167, MCF7 and 624mel) at a ratio of 1:1 for 6 hours and then washed and cultured for another 7 days with or without cytokines (100U/ml IL-2, 20ng/ml IL-7, IL12). On day 7, T cell controls and tumor-exposed cells were evaluated for the loss of CD27 and CD28. Representative dot plots depicting CD27−CD28− T cells induced by Tu167 are shown in (A). Tumor-exposed T cells incubated with different tumor cells (from at least three independent experiments) in the presence or absence of different cytokines are shown in (B), error bars represent standard deviation. (C) Analysis of telomere length with freshly isolated T cells, T cells on day 7 and tumor-exposed T cells on day 7 (+/−IL-2, IL- 7, or IL-12). The bar chart shows the standard error of the mean (SEM) relative telomere length (RTL) in cells from 3 independent experiments.*, P=0.027 versus control tumor-exposed cells. NS, no statistical significance between IL-7 treated, tumor-exposed cells and untreated T cells alone.